CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Get a quick snapshot of today’s dividend ETF expense ratios and what they mean for your potential returns, with tips for comparing funds.
18,562 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Hidden Road's NSCC integration marks a milestone for Ripple's XRP ecosystem as RLUSD grows, boosting liquidity and in...
A new Xbox CEO rises amid a changing gaming landscape. Her career path—from janitorial work to coupon sales to the C-...
Nvidia leads the AI chip race, but AMD has momentum and strategic wins. This guide breaks down who is the better arti...
The quantum computing sector has faced a pullback, but not every hire is a misfire. This article breaks down the rece...
When the S&P 500 posted best quarterly performance, markets flashed a signal that traders will debate for weeks. This...
The SK Hynix IPO set a new milestone, underscoring soaring demand for AI memory. This article breaks down what hynix ...
Microsoft stock has slipped in 2026, but a strong earnings report could ignite a rebound. This guide breaks down what...
Two AI-driven stocks with durable moats and solid cash flow could deliver outperformance over the next five years. Ex...
Anchorage Digital confirms it holds Strategy’s STRC perpetual preferred stock, marking a high-profile move by a regul...
Oracle’s shares have fallen sharply this year, leaving investors wondering if the decline creates a buying opportunit...
Markets often move on signals, not speeches. This piece breaks down why trump's state union address sparked relief in...